131 related articles for article (PubMed ID: 23877793)
1. K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin.
Ma Y; Guo FC; Wang W; Shi HS; Li D; Wang YS
Mol Med Rep; 2013 Sep; 8(3):763-8. PubMed ID: 23877793
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
3. [Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo].
Zhang ZP; Jiang GC; Yang F; Zhou ZL; Wang J
Zhonghua Wai Ke Za Zhi; 2007 Sep; 45(18):1267-70. PubMed ID: 18067742
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
6. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo.
Jasinski P; Zwolak P; Terai K; Dudek AZ
Transl Res; 2008 Nov; 152(5):203-12. PubMed ID: 19010291
[TBL] [Abstract][Full Text] [Related]
7. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin.
Suwei D; Liang Z; Zhimin L; Ruilei L; Yingying Z; Zhen L; Chunlei G; Zhangchao L; Yuanbo X; Jinyan Y; Gaofeng L; Xin S
J Hematol Oncol; 2015 Oct; 8():120. PubMed ID: 26503334
[TBL] [Abstract][Full Text] [Related]
8. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
9. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
Iglesias DA; Yates MS; van der Hoeven D; Rodkey TL; Zhang Q; Co NN; Burzawa J; Chigurupati S; Celestino J; Bowser J; Broaddus R; Hancock JF; Schmandt R; Lu KH
Mol Cancer Ther; 2013 Dec; 12(12):2847-56. PubMed ID: 24077915
[TBL] [Abstract][Full Text] [Related]
10. [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells].
Shen YM; Yang XC; Zhang MH; Shen JK; Sun YH
Ai Zheng; 2008 May; 27(5):496-504. PubMed ID: 18479599
[TBL] [Abstract][Full Text] [Related]
11. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
Kong M; Fan J; Dong A; Cheng H; Xu R
Acta Biochim Biophys Sin (Shanghai); 2010 Nov; 42(11):827-33. PubMed ID: 20978038
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
Zhang XH; Shin JY; Kim JO; Oh JE; Yoon SA; Jung CK; Kang JH
Cancer Lett; 2012 Sep; 322(2):213-22. PubMed ID: 22433711
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
[TBL] [Abstract][Full Text] [Related]
14. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
Khanzada UK; Pardo OE; Meier C; Downward J; Seckl MJ; Arcaro A
Oncogene; 2006 Feb; 25(6):877-87. PubMed ID: 16170339
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
[TBL] [Abstract][Full Text] [Related]
18. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
[TBL] [Abstract][Full Text] [Related]
19. Induction of CTLs by DCs pulsed with K-ras mutant peptide on the surface of nanoparticles in the treatment of pancreatic cancer.
Tan G; Wang Z; Zhang X; Cai Z; Zhang J
Oncol Rep; 2011 Jul; 26(1):215-21. PubMed ID: 21573499
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions.
Zhang Y; Meng X; Tang H; Cheng M; Yang F; Xu W
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):344-353. PubMed ID: 31851852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]